Because of many reasons, such as secondary mutations, tumor heterogeneity, and driving gene conversion, which may cause drug resistance (Doebele et al., 2012), second- and third-generation ALK-TKIs have been researched and developed. This evidence concerns the gene ALK and neoplasm.